2 Reasons Investors Should Buy Chewy Stock

Chewy generated $12.6 billion in fiscal 2025 net sales, up 6% year over year, while operating income rose 125% and free cash flow increased 24% to $562 million. The article argues the stock looks more attractive after a near-80% drop from its all-time high, with a forward P/E of 16 versus a trailing P/E of 50 and analysts forecasting 9% sales growth and 28% net income growth next year. The tone is constructive on fundamentals and valuation, though the piece is opinion-driven rather than a new company announcement.

Analysis

The market is still pricing CHWY like a low-quality discretionary name, but the business is behaving more like a recurring-revenue platform with an attach-rate flywheel. The second-order effect is that incremental spend on pharmacy, telehealth, and clinics should raise customer lifetime value and reduce price sensitivity in the core basket, which matters more than headline revenue growth in the high single digits. If that mix shift persists, margin expansion can continue even without a re-acceleration in top-line growth.

The real setup is multiple expansion driven by visibility, not excitement. At a forward multiple in the mid-teens, the stock only needs modest execution consistency for institutions to start underwriting it as a durable compounder rather than a post-pandemic retracement story. The bigger beneficiary may be the broader pet-health ecosystem: suppliers, prescription logistics, and clinic buildout partners should see steadier demand as Chewy pushes deeper into higher-margin services.

The main risk is that the market underestimates how sensitive the thesis is to reinvestment cadence. If Chewy chooses to keep leaning into clinic openings or service expansion, near-term operating leverage could flatten and the stock may not rerate until investors get proof that monetization scales faster than opex. A weaker consumer or pet spending normalization would not need to break revenue growth to hurt the stock; it would be enough for growth to slow from high-single-digits to low-single-digits, which would compress the multiple quickly.

Consensus seems to be missing that this is now partly a quality-of-earnings story: free cash flow and service mix matter more than one-off net income comparisons. The stock is likely not a momentum trade; it is a 6-12 month re-rating candidate if management keeps converting traffic into higher-value, stickier services. That makes the asymmetry attractive, but only if execution remains disciplined.

Key Decisions for Investors

• Initiate a medium-term long CHWY position on weakness for a 6-12 month rerating trade; target is expansion toward a 20x+ forward multiple if service mix and FCF growth hold, with downside capped by already-depressed sentiment.
• Structure a CHWY call spread expiring in 6-9 months to express upside from multiple expansion while limiting exposure if clinic rollout temporarily compresses margins.
• Pair long CHWY vs short a lower-quality discretionary retailer basket over the next 3-6 months; the relative setup favors a recurring, service-attach model over pure transactional retail.
• Add a watchlist long on pet-health/service beneficiaries with CHWY exposure catalyst risk; if clinic expansion accelerates, suppliers and adjacent service providers could see a second-order demand tailwind.
• Use a hard stop if forward revenue growth trends toward low-single-digits for two consecutive quarters; that would likely break the rerating thesis and re-anchor the stock to a value trap multiple.